The Medicines Company CEO Clive Meanwell is circling all the wagons around its late-stage PCSK9 development plans for inclisiran.
Clive Meanwell, The Medicines Company
The Alnylam partner said today that once the biotech completes an effort to sell off its infectious disease group, the company which had 410 staffers in February will chop its remaining work force down to a more affordable group of less than 60 staffers.
Meanwell had already put out word that he was looking for the best deal possible for the infectious disease business as the Parsipanny, NJ-based biotech zeroes in on an LDL lowering therapy that has the potential to overtake the leaders in the field: Regeneron and Sanofi as well as their chief rival Amgen…
Read the full article at: https://endpts.com/the-medicines-company-brings-out-the-ax-looking-to-jettison-hundreds-of-jobs-in-top-to-bottom-restructuring/